Intercept Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Intercept Pharmaceuticals

27/04/2023 16:52

* Intercept Pharmaceuticals Inc  ICPT.OQ  reported a
quarterly
adjusted loss of 77 cents​​ per share for the quarter ended in
March. The mean expectation of fourteen analysts for the quarter
was for a loss of 65 cents per share.
    * Revenue fell 23.3% to $67.96 million from a year ago;
analysts
expected $72.22 million. 
    * Intercept Pharmaceuticals Inc's reported EPS for the
quarter was
a loss of 77 cents​.
    * The mean earnings estimate of analysts had fallen by
about 5.8%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate 
    * Intercept Pharmaceuticals Inc shares had risen by 36.6%
this
quarter and gained 48.3% so far this year.
    * The company reported a quarterly loss of $32.14 million.
    * Wall Street's median 12-month price target for Intercept
Pharmaceuticals Inc is $21.00 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 9
"hold" and 2 "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
April 27 at 03:52 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.65          -0.77          Missed
 Dec. 31 2022      -0.16          -0.50          Missed
 Sep. 30 2022      4.61           7.80           Beat
 Jun. 30 2022      -0.49          -0.68          Missed